Also known as: Neurocrine
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07611786 |
Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia |
NOT_YET_RECRUITING | |
| NCT07365462 |
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia |
RECRUITING | PHASE2 |
| NCT07288333 |
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia |
RECRUITING | PHASE2 |
| NCT07288320 |
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania |
RECRUITING | PHASE2 |
| NCT07227818 |
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia |
RECRUITING | PHASE3 |
| NCT07196501 |
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) |
RECRUITING | PHASE3 |
| NCT07187375 |
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07114874 |
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia |
RECRUITING | PHASE3 |
| NCT07111988 |
Valbenazine in Obsessive Compulsive Disorder |
NOT_YET_RECRUITING | PHASE2 |
| NCT07105111 |
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor |
RECRUITING | PHASE4 |
